**Core tip:** This was a prospective single center study with 322 consecutive patients with chronic heart failure (CHF) seeking to evaluate the feasibility of combined assessment of biochemical and electrophysiological markers of myocardial impairment for risk-stratifying patients with CHF. QRS prolongation and high heart-type fatty acid binding protein levels are independently associated with cardiac events in patients with CHF.

INTRODUCTION
============

Chronic heart failure (CHF) is a major health problem with high mortality despite advance in medical therapy\[[@B1]-[@B3]\]. Various pathophysiological changes are reportedly associated with initiation and progression in CHF\[[@B4]\]. The role of biomarkers continues to increase in importance to evaluate and risk-stratify CHF patients\[[@B5]\].

Heart-type fatty acid binding protein (H-FABP) is a small molecule protein (14-15 kDa), abundant in cytoplasm of cardiomyocytes and easily leaks to the circulation from damaged myocardium\[[@B6]-[@B8]\]. H-FABP is a potential myocardial damage marker. We and others reported that elevated serum H-FABP levels can predict poor outcomes in patients with CHF\[[@B9],[@B10]\]. Progression of CHF is associated with persistent loss of cardiomyocytes, which can be clinically detected as a continuous increase in serum H-FABP levels\[[@B11]\].

Electrocardiography (ECG) is routinely performed and is useful for evaluating the etiology of heart failure. Several electrocardiographic parameters were reported to predict poor outcome in HF patients\[[@B12]-[@B14]\]. QRS prolongation indicated electrical disturbance and is associated with left ventricular dyssynchrony and poor cardiac prognosis in patients with CHF\[[@B15]-[@B17]\]. Not surprisingly, due to the complex pathogenesis of CHF, a single biomarker cannot be used to predict the absolute risk of future cardiac events. Therefore, the purpose of the present study was to investigate whether a combined measurement of a myocardial damage marker and electrical disturbance can be used to risk-stratify CHF patients.

MATERIALS AND METHODS
=====================

Study population
----------------

We prospectively studied 322 patients with CHF, who were admitted to our hospital for the diagnosis or treatment of CHF. The diagnosis of CHF was made by two cardiologists who used the generally accepted Framingham criteria, including a history of dyspnea and symptomatic exercise intolerance, signs of pulmonary congestion, peripheral edema, and radiologic or echocardiographic evidence of left ventricular enlargement or dysfunction. Demographic and clinical data including age, gender, New York Heart Association (NYHA) functional class, and medications at discharge were obtained from hospital medical records and interviews with patients. The diagnoses of hypertension, diabetes mellitus and hyperlipidemia were ascertained from the medical records or current or previous medical therapy. Glomerular filtration rate (GFR) was estimated using the modification of diet in renal disease equation with the Japanese coefficient, as previously reported\[[@B18]\]. The exclusion criteria for the present study were acute coronary syndrome, bundle branch block, pace maker implantation, a serum creatinine concentration \> 2.0 mg/dL, and implantation of a heart valve prosthesis.

Electrocardiographic and echocardiographic studies
--------------------------------------------------

Standard 12-lead ECG was performed at admission. QRS duration was measured by averaging of all heartbeats all leads. A normal QRS duration was defined as less than 120 ms and a prolonged QRS as 120 ms or longer. Transthoracic echocardiography was performed by physicians who were blinded to the biochemical data.

Assay of H-FABP and brain natriuretic peptide concentrations
------------------------------------------------------------

Venous blood samples were obtained at admission for measurements of serum H-FABP levels. These samples were immediately centrifuged at 2500 G for 15 min at 4 °C. The clarified serum samples were frozen, stored at -70 °C, and thawed just before assay. H-FABP concentration was measured using a two-step sandwich enzyme-linked immunosorbent assay kit (MARKIT-M HFABP, Dainippon Pharmaceutical Co Ltd, Tokyo, Japan) as previously reported\[[@B19],[@B20]\]. The cut-off value for H-FABP concentration (4.5 ng/mL) was determined from a previous study\[[@B21]\]. The same blood samples were used for measurement of plasma brain natriuretic peptide (BNP) concentrations. The samples were transferred to chilled tubes containing of ethylene diamine tetraacetic acid disodium salt (4.5 mg) and aprotinin (500 U/mL), and immediately centrifuged at 1000 G for 15 min at 4 °C. The clarified plasma samples were frozen, stored at -70 °C and thawed just before assay. BNP concentrations were measured using a commercially available specific radioimmunoassay for human BNP (Shiono RIA BNP assay kit, Shionogi Co Ltd, Tokyo, Japan). The analytical ranges, and intra- and inter-assay coefficients of variation for the H-FABP and BNP assays were, 1.1-250 ng/mL, 3% and 3.5%, and 4.0-2000 pg/mL, 10.9% and 10.6%, respectively.

End points and follow-up
------------------------

Patients were prospectively followed for a median period of 534 d (range 203-1014). Patients were followed in our hospital outpatient clinic every month. The other patients were followed by telephone twice a year until 2555 d after discharge. The end points were cardiac death, defined as death due to progressive heart failure, myocardial infarction or sudden cardiac death, and progressive heart failure requiring rehospitalization. Sudden cardiac death was defined as death without definite premonitory symptoms or signs, and was established by the attending physician. The study was approved by the Institutional Ethics Committee, and all patients gave written informed consent prior to participating. The study was performed in accordance with the Helsinki Declaration.

Statistical analysis
--------------------

Results are presented as the mean values ± SD for continuous variables and as percentages of the total number of patients for categorical variables. The independent samples *t* test and χ^2^ test or linear regression analysis were used for comparison of continuous and categorical variables, respectively. A Cox proportional hazard analysis was performed to assess the independent predictors for cardiac events in the entire population. Statistical significance was defined as *P* \< 0.05. Variables identified as significant by univariate analysis were entered into the multivariate analysis. The cardiac event-free curve was computed according to the Kaplan-Meier method, and comparison of cardiac event-free survival between subgroups was performed using the log-rank test. Receiver operating characteristic (ROC) curve analysis, as well as area under the curve (AUC) was used as measures of the predictive accuracy of traditional prognostic factors for cardiac events. In addition, the net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were calculated in order to quantify the improvement for the corrected re-classification and sensitivity after inclusion of high H-FABP levels and QRS prolongation in the model. Statistical analyses were performed using a standard software package (JMP version 8; SAS Institute Inc., Cary, NC, United States) or R 3.0.2 with additional packages (Rcmdr, Epi, pROC and PredictABEL).

RESULTS
=======

Patient characteristics
-----------------------

Table [1](#T1){ref-type="table"} shows that clinical characteristics of the study patients. The mean age of the patients was 69 ± 13 years. There were 175 patients in NYHA functional class II, 105 in NYHA class III, and 42 in NYHA class IV. Diabetes mellitus, dyslipidemia, and hypertension were identified in 117 (36%), 87 (26%), and 217 (67%) of the CHF patients, respectively. The etiology of heart failure was dilated cardiomyopathy in 80 (25%) patients, hypertensive heart disease in 14 (4%), hypertrophic cardiomyopathy in 21 (7%), ischemic heart disease in 65 (20%), valvular heart disease in 80 (25%), arrhythmia in 24 (7%), and other etiologies in 38 (12%) patients. The median H-FABP and BNP levels were 4.7 (3.3-7.6) ng/mL and 397 (135-853) pg/mL, respectively. The mean QRS duration was 107 ± 20 ms and 61 patients (19%) showed QRS prolongation. Simple linear regression analysis showed that QRS duration was not correlated with H-FABP level (*r* = 0.091, *P* = 0.1019) or BNP level (*r* = 0.066, *P* = 0.2356) as shown in Figure [1](#F1){ref-type="fig"}.

###### 

Comparison of the clinical characteristics of patients with and without cardiac events

                                        **All patients (*n* = 322)**   **Event-free (*n* = 205)**   **Cardiac event (*n* = 117)**   ***P* value**
  ------------------------------------- ------------------------------ ---------------------------- ------------------------------- ---------------
  Age, yr                               69 ± 13                        67 ± 14                      72 ± 11                         0.0041
  Female, *n* (%)                       140 (43)                       92 (45)                      48 (41)                         0.5024
  NYHA functional class, II/III/IV      175/105/42                     125/53/27                    50/52/15                        0.002
  Etiology, *n* (%)                                                                                                                 0.5273
  Dilated cardiomyopathy                80 (25)                        56 (27)                      24 (21)                         
  Hypertensive heart disease            14 (4)                         10 (5)                       4 (3)                           
  Hypertrophic cardiomyopathy           21 (7)                         15 (7)                       6 (5)                           
  Ischemic heart disease                65 (20)                        36 (18)                      29 (25)                         
  Valvular heart disease                80 (25)                        52 (25)                      28 (24)                         
  Arrhythmia                            24 (7)                         14 (7)                       10 (8)                          
  Others                                38 (12)                        22 (11)                      16 (14)                         
  Atrial fibrillation, *n* (%)          109 (34)                       64 (31)                      45 (38)                         0.1866
  Diabetes mellitus, *n* (%)            117 (36)                       71 (35)                      44 (38)                         0.5923
  Dyslipidemia, *n* (%)                 87 (26)                        56 (26)                      31 (27)                         0.8732
  Hypertension, *n* (%)                 217 (67)                       137 (67)                     80 (68)                         0.7758
  Blood biomarkers                                                                                                                  
  BNP, pg/mL (IQR)                      397 (135-853)                  314 (101-710)                625 (280-1147)                  0.0326
  H-FABP, ng/mL (IQR)                   4.7 (3.3-7.6)                  4.0 (2.9-6.3)                6.0 (4.2-10.0)                  \< 0.0001
  eGFR, mL/min per 1.73 m^2^            65 ± 22                        69 ± 23                      58 ± 19                         \< 0.0001
  Echocardiographic data                                                                                                            
  LV end-diastolic diameter, mm         55 ± 10                        54 ± 9                       55 ± 12                         0.6018
  LV ejection fraction, %               49 ± 18                        50 ± 18                      47 ± 18                         0.1472
  Electrocardiogram                                                                                                                 
  Heart rate, beat/min                  77 ± 22                        78 ± 21                      74 ± 19                         0.0841
  QRS duration, ms                      107 ± 20                       106 ± 18                     109 ± 22                        0.0989
  QRS prolongation, *n* (%)             61 (19)                        28 (17)                      33 (28)                         0.0014
  Medications, *n* (%)                                                                                                              
  ACE inhibitors and/or ARBs, *n* (%)   213 (66)                       138 (67)                     75 (64)                         0.5577
  β-blockers, *n* (%)                   170 (53)                       106 (52)                     64 (55)                         0.6048
  Ca channel blockers, *n* (%)          66 (21)                        41 (21)                      25 (20)                         0.77
  Diuretics, *n* (%)                    202 (63)                       111 (54)                     91 (78)                         \< 0.0001
  Statins, *n* (%)                      83 (26)                        54 (26)                      29 (25)                         0.759

Data are presented as mean ± SD or % unless otherwise indicated. ACE: Angiotensin-converting enzyme; ARB: Angiotensin receptor blocker; BNP: Brain natriuretic peptide; eGFR: Estimated glomerular filtration rate; H-FABP: Heart-type fatty acid-binding protein; LV: Left ventricular; NYHA: New York Heart Association.

![Relationship between QRS duration and heart-type fatty acid binding protein levels (A) and brain natriuretic protein levels (B). BNP: Brain natriuretic peptide; H-FABP: Heart-type fatty acid-binding protein.](WJC-9-457-g001){#F1}

Clinical outcomes
-----------------

During the follow-up period, there were 117 primary events, including 27 cardiac deaths and 90 re-admissions for worsening CHF. Among 27 cardiac deaths, there were 21 deaths from worsening CHF, 2 fatal acute myocardial infarction, and 4 sudden cardiac deaths. The patients with cardiac events were older and had a more severe NYHA functional class compared to those who did not (Table [1](#T1){ref-type="table"}). Furthermore, higher BNP and H-FABP levels, and a higher prevalence of QRS prolongation were observed in patients who experienced cardiac events, compared with those who did not. Patients who experienced cardiac events also had a lower estimated GFR (eGFR) compared with those who did not. There was no difference in gender, prevalence of atrial fibrillation, hypertension, diabetes mellitus or hyperlipidemia between CHF patients with and without cardiac events. Patients who experienced cardiac events took loop diuretics more frequently than patients who were event-free.

Independent predictors of cardiac events
----------------------------------------

To investigate the risk factors for cardiac events, Cox proportional hazards regression analyses were performed (Table [2](#T2){ref-type="table"}). In the univariate analysis, high H-FABP levels and QRS prolongation were significantly associated with cardiac events. Further, age, NYHA functional class, BNP levels, and eGFR were significantly associated with cardiac events. In the multivariate analysis, NYHA functional class, eGFR, high serum H-FABP levels, and prolonged QRS duration were independently associated with cardiac events.

###### 

Univariate and multivariate analyses for cardiovascular events

                                                **HR**   **95%CI**     ***P* value**
  --------------------------------------------- -------- ------------- ---------------
  Univariate analysis                                                  
  Age, per 10-yr increase                       1.297    1.105-1.524   0.0016
  Female gender                                 0.829    0.573-1.199   0.3183
  NYHA functional class II and III *vs* IV      1.960    1.381-2.747   0.0003
  Atrial fibrillation                           1.256    0.865-1.824   0.2304
  Diabetes mellitus                             1.103    0.758-1.605   0.6062
  Dyslipidemia                                  0.958    0.635-1.447   0.8417
  Hypertension                                  0.986    0.667-1.457   0.9459
  BNP, per 1SD increase                         1.166    1.019-1.334   0.0249
  eGFR, per 1SD increase                        0.589    0.467-0.733   \< 0.0001
  LV end-diastolic diameter, per 1SD increase   1.062    0.877-1.280   0.5272
  LV ejection fraction, per 1SD increase        0.881    0.734-1.074   0.1998
  Heart rate, per 1SD increase                  0.869    0.724-1.062   0.1724
  High H-FABP (\> 4.5 ng/mL)                    2.994    1.996-4.504   \< 0.0001
  QRS prolongation (≥ 120 ms)                   1.897    1.264-2.832   0.0019
  Multivariate analysis                                                
  Age, per 10-yr increase                       1.093    0.921-1.298   0.3055
  NYHA functional class II and III *vs* IV      1.55     1.055-2.309   0.0262
  BNP, per 1SD increase                         0.948    0.811-1.151   0.7003
  eGFR, per 1SD increase                        0.733    0.571-0.938   0.0144
  High H-FABP (\> 4.5 ng/mL)                    1.745    1.088-2.793   0.0210
  QRS prolongation (≥ 120 ms)                   1.612    1.060-2.451   0.0258

HR: Hazard ratio; SD: Standard deviation; BNP: Brain natriuretic peptide; eGFR: Estimated glomerular filtration rate; NYHA: New York Heart Association.

A combined assessment of QRS duration and H-FABP level
------------------------------------------------------

Simple linear analysis demonstrated that QRS duration was not correlated with H-FABP or BNP levels in patients with CHF (Figure [1](#F1){ref-type="fig"}). The patients were divided into four groups based on QRS prolongation and H-FABP cutoff values as shown in Figure [2](#F2){ref-type="fig"}: (1) normal group (*n* = 136), H-FABP ≤ 4.5 ng/mL, QRS duration \< 120 ms; (2) QRS prolongation group (*n* = 20), H-FABP ≤ 4.5 ng/mL, QRS ≥ 120 ms; (3) high H-FABP group (*n* = 125), H-FABP \> 4.5 ng/mL, QRS duration \< 120 ms; and (4) high H-FABP + QRS prolongation group (*n* = 41), H-FABP \> 4.5 ng/mL, QRS duration ≥ 120 ms. High serum H-FABP + QRS prolongation group showed the highest rates of cardiac deaths and cardiac events (*P* \< 0.001). Multivariate Cox hazard analysis revealed that after adjustment for age, NYHA functional class, BNP levels and eGFR, the QRS prolongation, high H-FABP, and high H-FABP + QRS prolongation groups had 1.61-fold (*P* \< 0.05), 1.74-fold (*P* \< 0.05), and 2.81-fold higher risks of cardiac events (*P* \< 0.01), respectively, compared with the normal group (Figure [3](#F3){ref-type="fig"}). The characteristics of these four groups are presented in Table [3](#T3){ref-type="table"}. The QRS prolongation group had lower BNP levels than the high H-FABP and high H-FABP + QRS prolongation groups. The QRS prolongation group also had the lowest left ventricular (LV) ejection fraction and largest LV end-diastolic diameter among 4 groups. Kaplan-Meier analysis demonstrated that the high H-FABP + QRS prolongation group had a significantly higher rate of cardiac events than the other groups (Figure [4](#F4){ref-type="fig"}). In order to examine whether model fit and discrimination improved with the addition of high H-FABP levels and QRS prolongation to the traditional prognostic factors of age, BNP level, NYHA functional class and eGFR, the differences in area under the ROC curves, and the improvement in NRI and IDI were evaluated for two models: With (group 2) or without (group 1) a high H-FABP level and QRS prolongation. The area under the ROC curve for predicted cardiac events was significantly greater for group 2 than group 1 (Table [4](#T4){ref-type="table"}). Further, the group 2 model improved the NRI and IDI values for predicting cardiac events compared with the group 1 model.

![Cardiac mortality and all cardiac events among the four groups based on heart-type fatty acid-binding protein level and QRS duration. Normal group (*n* = 136), H-FABP ≤ 4.5 ng/mL and QRS duration \< 120 ms; QRS prolongation group (*n* = 20), H-FABP ≤ 4.5 ng/mL and QRS duration ≥ 120 ms; high H-FABP group (*n* = 125), H-FABP \> 4.5 ng/mL and QRS duration \< 120 ms; and high H-FABP + QRS prolongation group (*n* = 41), H-FABP \> 4.5 ng/mL and QRS duration ≥ 120 ms. H-FABP: Heart-type fatty acid-binding protein.](WJC-9-457-g002){#F2}

###### 

Clinical characteristics of the 4 subgroups of chronic heart failure patients

                                        **Normal (*n* = 136)**   **QRS prolongation (*n* = 20)**                                            **High H-FABP (*n* = 125)**                                                      **High H-FABP and QRS prolongation (*n* = 41)**
  ------------------------------------- ------------------------ -------------------------------------------------------------------------- -------------------------------------------------------------------------------- -------------------------------------------------------------------------------
  Age, yr                               65 ± 13                  59 ± 11                                                                    74 ± 11[a](#T3FN1){ref-type="table-fn"}[b](#T3FN2){ref-type="table-fn"}          71 ± 13[b](#T3FN2){ref-type="table-fn"}
  Female, *n* (%)                       58 (42)                  10 (50)                                                                    55 (45)                                                                          17 (41)
  NYHA functional class, II/III/IV      97/30/9                  3/4/2013                                                                   51/54/20                                                                         14/18/9[e](#T3FN5){ref-type="table-fn"}
  Etiology, *n* (%)                                                                                                                                                                                                          
  Dilated cardiomyopathy                33 (24)                  8 (40)                                                                     24 (19)                                                                          15 (37)
  Hypertensive heart disease            8 (6)                    1 (5)                                                                      5 (4)                                                                            1 (2)
  Hypertrophic cardiomyopathy           11 (8)                   3 (15)                                                                     6 (5)                                                                            0 (0)
  Ischemic heart disease                21 (15)                  3 (15)                                                                     31 (24)                                                                          10 (24)
  Valvular heart disease                40 (30)                  3 (15)                                                                     29 (24)                                                                          8 (20)
  Arrhythmia                            12 (9)                   0 (0)                                                                      8 (7)                                                                            4 (10)
  Others                                11 (8)                   2 (10)                                                                     22 (17)                                                                          3 (7)
  Atrial fibrillation, *n* (%)          48 (35)                  7 (35)                                                                     41 (33)                                                                          13 (32)
  Diabetes mellitus, *n* (%)            46 (33)                  6 (28)                                                                     46 (37)                                                                          17 (41)
  Dyslipidemia, *n* (%)                 39 (28)                  4 (20)                                                                     32 (26)                                                                          12 (29)
  Hypertension, *n* (%)                 92 (67)                  11 (55)                                                                    89 (72)                                                                          25 (61)
  Blood biomarkers                                                                                                                                                                                                           
  BNP, pg/mL (IQR)                      347 (69-453)             389 (213-855)                                                              700 (311-1257)[a](#T3FN1){ref-type="table-fn"}                                   628 (328-1075)[a](#T3FN1){ref-type="table-fn"}
  H-FABP, ng/mL (IQR)                   3.2 (2.4-3.9)            3.6 (2.8-4.2)                                                              7.6 (5.7-11.0)[a](#T3FN1){ref-type="table-fn"}[b](#T3FN2){ref-type="table-fn"}   7.6 (5.7-9.8)[a](#T3FN1){ref-type="table-fn"}[b](#T3FN2){ref-type="table-fn"}
  eGFR, mL/min per 1.73 m^2^            75 ± 20                  71 ± 26                                                                    57 ± 20[a](#T3FN1){ref-type="table-fn"}                                          52 ± 17[a](#T3FN1){ref-type="table-fn"}[d](#T3FN4){ref-type="table-fn"}
  Echocardiographic data                                                                                                                                                                                                     
  LV end-diastolic diameter, mm         52 ± 10                  65 ± 9[a](#T3FN1){ref-type="table-fn"}[d](#T3FN4){ref-type="table-fn"}     54 ± 9[b](#T3FN2){ref-type="table-fn"}                                           60 ± 10[a](#T3FN1){ref-type="table-fn"}[c](#T3FN3){ref-type="table-fn"}
  LV ejection fraction, %               55 ± 18                  35 ± 15[a](#T3FN1){ref-type="table-fn"}                                    49 ± 17[b](#T3FN2){ref-type="table-fn"}                                          38 ± 14[a](#T3FN1){ref-type="table-fn"}[d](#T3FN4){ref-type="table-fn"}
  Electrocardiogram                                                                                                                                                                                                          
  Heart rate, beat/min                  78 ± 19                  72 ± 13                                                                    79 ± 22                                                                          72 ± 20
  QRS duration, ms                      100 ± 10                 143 ± 23[a](#T3FN1){ref-type="table-fn"}[d](#T3FN4){ref-type="table-fn"}   100 ± 10                                                                         138 ± 14[a](#T3FN1){ref-type="table-fn"}[d](#T3FN4){ref-type="table-fn"}
  Medications, *n* (%)                                                                                                                                                                                                       
  ACE inhibitors and/or ARBs, *n* (%)   86 (62)                  13 (65)                                                                    85 (69)                                                                          29 (71)
  β-blockers, *n* (%)                   65 (47)                  15 (75)                                                                    64 (52)                                                                          26 (63)
  Ca channel blockers, *n* (%)          36 (26)                  0 (0)                                                                      24 (20)                                                                          6 (15)
  Diuretics, *n* (%)                    72 (52)                  14 (70)                                                                    82 (67)                                                                          34 (83)[e](#T3FN5){ref-type="table-fn"}
  Statins, *n* (%)                      40 (29)                  5 (25)                                                                     28 (23)                                                                          10 (24)

*P* \< 0.01 *vs* normal;

*P* \< 0.01 *vs* QRS prolongation; and

*P* \< 0.05 and

*P* \< 0.01 *vs* High H-FABP by analysis of variance with the Scheffe post hoc test.

*P* \< 0.01 by *χ*^2^ test. Normal group (*n* = 136): H-FABP ≤ 4.5 ng/mL and QRS duration \< 120 ms, QRS prolongation group (*n* = 20): H-FABP ≤ 4.5 ng/mL and QRS duration ≥ 120 ms, High H-FABP group (*n* = 123): H-FABP \> 4.5 ng/mL and QRS duration \< 120 ms, and High H-FABP and QRS prolongation group (*n* = 41): H-FABP \> 4.5 ng/mL and QRS duration ≥ 120 ms. ACE: Angiotensin-converting enzyme; ARB: Angiotensin receptor blocker; BNP: Brain natriuretic peptide; eGFR: Estimated glomerular filtration rate; H-FABP: Heart-type fatty acid-binding protein; LV: Left ventricular; NYHA: New York Heart Association.

![Hazard ratios relative to the normal group after adjustment for age, New York Heart Association functional class, brain natriuretic peptide level and estimated glomerular filtration rate. ^a^*P* \< 0.05, ^b^*P* \< 0.01 *vs* normal group. H-FABP: Heart-type fatty acid-binding protein.](WJC-9-457-g003){#F3}

###### 

Statistics for model fit and improvement with the addition of high heart-type fatty acid-binding protein and QRS prolongation predicted on the prediction of cardiac events

                     **Group 1**   **Group 2**           ***P* value**
  ------------------ ------------- --------------------- ---------------
  AUC of ROC curve   0.668         0.706                 0.029
  NRI (95%CI)        Ref           0.223 (0.073-0.372)   0.003
  IDI (95%CI)        Ref           0.036 (0.015-0.056)   0.016

AUC: Area under the curve; CI: Confidence interval; IDI: Integrated discrimination improvement; NRI: Net reclassification improvement; ROC: Receiver operator characteristics. Group 1: Age + BNP + NYHA + eGFR; Group 2: Group 1 + H-FABP \> 4.5 ng/mL + QRS duration ≥ 120 ms. BNP: Brain natriuretic peptide; eGFR: Estimated glomerular filtration rate; H-FABP: Heart-type fatty acid-binding protein; NYHA: New York Heart Association.

![Kaplan-Meier analysis of the cardiac event-free curve in patients with chronic heart failure, who were stratified into four groups based on QRS duration and heart-type fatty acid-binding protein level. H-FABP: Heart-type fatty acid-binding protein.](WJC-9-457-g004){#F4}

DISCUSSION
==========

In the present study, we demonstrated that QRS prolongation as a marker of electrical disturbance, and high H-FABP levels as a marker of ongoing myocardial damage are significantly related to cardiac events in CHF patients. The inclusion of high H-FABP level and QRS prolongation with BNP level, NYHA functional class and eGFR in the model for predicting cardiac events improved the NRI and IDI values, indicating effective reclassification and discrimination. Therefore, a combined measurement of H-FABP levels and QRS duration is a promising strategy for risk stratification for future cardiac events in CHF patients.

There are several markers of myocardial damage, including troponin T, troponin I and H-FABP\[[@B9],[@B22]\]. Since H-FABP is a small cytosolic protein, it is readily released into the circulation when cardiomyocytes are injured. The mechanism by which serum levels of H-FABP are increased in CHF has been reported to be related to cardiomyocyte necrosis, apoptosis, chronic inflammation and microcirculatory disorder\[[@B8],[@B23]\]. In this study, elevated levels of H-FABP were significantly associated with cardiac events, which are consistent with previous reports\[[@B19],[@B24]\].

QRS duration reflects LV conduction disturbance, LV systolic dysfunction and LV dilation\[[@B25]\]. In this study, the QRS prolongation group had the lowest LV ejection fraction and the greatest LV end-diastolic diameter compared with the other groups. Since left bundle branch block is an unfavorable prognostic marker in CHF patients\[[@B26],[@B27]\], patients with bundle branch block were excluded from the present study. Therefore, QRS prolongation is an independent risk factor for cardiac events in patients with CHF, irrespective of bundle branch block. Recently, it was reported that cardiac resynchronization therapy (CRT) can improve the cardiac prognosis in patients with QRS prolongation\[[@B28],[@B29]\] and measurement of QRS duration has attracted widespread interest.

The present study showed that there was no correlation between QRS duration and H-FABP or BNP levels in patients with CHF. These results suggest that H-FABP and BNP levels and QRS duration reflect different pathophysiological backgrounds. In the multivariate analysis, high H-FABP levels and QRS prolongation were independent predictors of cardiac events. In addition, multivariate Cox hazard analysis revealed that the combination of elevated H-FABP levels and QRS prolongation was associated with the highest increase in risk for cardiac events (2.81-fold) compared with the normal group.

Taniguchi et al\[[@B30]\] reported that the combined measurement of BNP levels and QRS duration can be used to predict cardiac events in heart failure patients. We recently determined that the AUC for prediction of cardiac events in heart failure was greater for H-FABP level than for BNP level\[[@B10]\]. Both the sensitivity and the specificity for predicting cardiac events were significantly greater for H-FABP level than for BNP level, indicating that H-FABP level is superior to BNP level for predicting cardiac events in CHF patients\[[@B10]\]. In this study, BNP level was not associated with cardiac events in the multivariate analysis. A weak correlation between H-FABP levels and BNP levels was observed (data not shown), which was consistent with the results from a previous study\[[@B10]\]. H-FABP and BNP reflect different pathophysiological backgrounds as markers of left ventricular overload. Combined assessment of H-FABP as a biochemical marker of myocardial damage and QRS prolongation as an electrophysiological marker of myocardial impairment is a potentially useful method for risk-stratification in CHF patients.

This study has several limitations. The effect of changes in QRS duration and H-FABP level between the time of hospitalization and discharge were not evaluated. However, it was reported that QRS duration in patients with CHF did not change significantly over two years\[[@B31]\]. On the other hand, although H-FABP level is usually decreased at discharge, persistently elevated H-FABP levels were reported to be associated with adverse outcomes in patients with CHF\[[@B32]\]. Therefore, further research is needed to elucidate whether the combined assessment of H-FABP level at discharge and QRS prolongation can be used to more precisely predict the cardiac prognosis of patients with CHF.

In conclusion, the combined assessment of markers of ongoing myocardial damage and electrical disturbance can be used to risk-stratify patients with CHF.
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The combined assessment of markers of ongoing myocardial damage and electrical disturbance can risk-stratify patients with CHF.

Applications
------------

It may be difficult to predict prognosis of CHF patients using a single biomarker precisely. The combined assessment of commonly used biomarkers is easily applicable to clinical practice.

Terminology
-----------

Since heart-type fatty acid binding protein (H-FABP) is a low molecular weight protein and abundant in the cytosolic fraction of cardiomyocytes, it is rapidly released into the circulation from damaged myocardium. Therefore, H-FABP is a potential marker of ongoing myocardial damage.
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